As nNOS level is greatly reduced in DMD patients as well as skeletal-derived NO production is blunted, and taking into consideration multiple mechanisms controlled by NO, it was speculated that modulation of NO signaling pathway might serve as a possible therapy for dystrophy treatment (Fig. 5). This evidence concerns the gene NOS1 and Duchenne muscular dystrophy.